The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|December 17, 2015
CRF Health Selected by Top Tier Pharma Companies for Women's Oncology Trials
Advertisement
CRF Health, the leading global provider of eCOA solutions for the life sciences industry, announces agreements with two top tier pharmaceutical companies to support drug development initiatives in women's health. Selected for three high priority oncology studies for three new molecular entities, CRF Health's TrialMax® platform will support data capture for quality of life issues during the post-progression phase.
The three large scale studies into ovarian cancer and breast cancer will encompass 542 sites, 23 countries and almost 2,000 female trial participants, across the U.S, Europe and Asia Pacific. For post-progression studies, the move from paper-based data collection to electronic methods is vital to providing unobtrusive and convenient care for patients too ill to visit study sites. CRF Health's TrialMax Touch® handheld patient diary will be used to support patients during these critical multi-year research initiatives, driving the collection of data that enhances these sponsors' data packages.
"We are pleased to have been selected as a partner of choice for these important drug development initiatives in women's oncology", said John Blakeley, Chief Business Officer at CRF Health. "With experience supporting more than 90 oncology studies, we are at the forefront of electronic data collection in this area. Our solution has been selected due to its unique design which allows us to collect data from patients in sensitive circumstances. We have given careful consideration to design a system with a more holistic approach to data capture in these uniquely challenging studies, ensuring ease-of-use for patients while making certain care remains at the center of clinical trials."
For further information on CRF Health, please visit
About CRF Health
CRF Health is the leading provider of electronic Clinical Outcome Assessment (eCOA) solutions for global clinical trials. With experience in more than 650 trials, over 100 languages and across 74 countries, CRF Health’s TrialMax eCOA solutions consistently demonstrate the industry’s highest data accuracy, patient and site compliance, and patient retention.
CRF Health’s TrialMax eCOA solutions improve trial engagement by fitting into the lives of patients and seamlessly integrating into sites to maximize protocol compliance. Their eCOA solutions include PROs (Patient Reported Outcomes), ObsROs (Observer Reported Outcomes) and ClinROs (Clinician or Rater Reported Outcomes).
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
3
Where AI Governance in Clinical Development Falls Short
4
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
5